Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group.; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis..

J Pediatr. 2016 Feb;169:116-21.e2. doi: 10.1016/j.jpeds.2015.08.042. Epub 2015 Sep 19.

PMID:
26388208
2.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group.; TRANSPORT Study Group..

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

3.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators.; coordinators of the Epidemiologic Study of Cystic Fibrosis..

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

4.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis..

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

5.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.; North American Scientific Advisory Group for ESCF..

J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16.

6.

Burkholderia glumae infection in an infant with chronic granulomatous disease.

Weinberg JB, Alexander BD, Majure JM, Williams LW, Kim JY, Vandamme P, LiPuma JJ.

J Clin Microbiol. 2007 Feb;45(2):662-5. Epub 2006 Nov 29.

7.

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.

Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA 3rd, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT.

Genet Med. 2001 Mar-Apr;3(2):132-8.

PMID:
11286229
8.

Comparison of physical activity in adolescents with cystic fibrosis versus age-matched controls.

Britto MT, Garrett JM, Konrad TR, Majure JM, Leigh MW.

Pediatr Pulmonol. 2000 Aug;30(2):86-91.

PMID:
10922129
9.

Cystic fibrosis: combined hyperpolarized 3He-enhanced and conventional proton MR imaging in the lung--preliminary observations.

Donnelly LF, MacFall JR, McAdams HP, Majure JM, Smith J, Frush DP, Bogonad P, Charles HC, Ravin CE.

Radiology. 1999 Sep;212(3):885-9.

PMID:
10478261
10.

Preventive services received by adolescents with cystic fibrosis and sickle cell disease.

Britto MT, Garrett JM, Dugliss MA, Johnson CA, Majure JM, Leigh MW.

Arch Pediatr Adolesc Med. 1999 Jan;153(1):27-32.

PMID:
9894996
11.

Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study.

Britto MT, Garrett JM, Dugliss MA, Daeschner CW Jr, Johnson CA, Leigh MW, Majure JM, Schultz WH, Konrad TR.

Pediatrics. 1998 Feb;101(2):250-6.

PMID:
9445499

Supplemental Content

Loading ...
Support Center